RecruitingNot ApplicableNCT07693621

Intraperitoneal Dexmedetomidine Versus Magnesium as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy

Intraperitoneal Instillation of Dexmedetomidine Versus Magnesium Sulphate as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy

Sponsor

Alexandria University

Enrollment

80 participants

Start Date

May 3, 2026

Study Type

INTERVENTIONAL

Conditions

Dexmedetomidine Laparoscopic Cholecystectomy Magnesium Sulfate

Summary

Although both dexmedetomidine and magnesium sulphate have been individually evaluated as adjuvants to local anesthetics, direct comparisons between the two agents in intraperitoneal instillation during laparoscopic cholecystectomy remain limited. Understanding their relative efficacy and safety could provide valuable guidance for optimizing perioperative analgesia in these patients.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Bupivacaine 100 mg + dexmedetomidine 1 µg/kg and Bupivacaine 100 mg + magnesium sulphate 50 mg/kg for people with dexmedetomidine, laparoscopic cholecystectomy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.